MENLO PARK, Calif., Oct. 10, 2011 (GLOBE NEWSWIRE) -- Depomed, Inc. (Nasdaq:DEPO) announced today that GRALISE™ (gabapentin) tablets are now available as a new once-daily treatment for postherpetic neuralgia (PHN), the pain following healing of the rash associated with shingles. GRALISE is available by prescription in a 30-day starter pack, which allows titration of the drug to full dose in 15 days, as well as bottles of 600 mg and 300 mg tablets. GRALISE is a proprietary formulation of gabapentin, using patented polymer technology that enables gradual release of the drug. GRALISE has a favorable safety profile.
